NCT07503808 is a Phase 1 clinical trial of IDE034 in Esophageal Squamous Cell Carcinoma, sponsored by IDEAYA Biosciences.

Who is sponsoring NCT07503808?

NCT07503808 is sponsored by IDEAYA Biosciences.

What drugs are being tested in NCT07503808?

Interventions in NCT07503808: IDE034.

What condition does NCT07503808 study?

NCT07503808 studies Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Castration-resistant Prostate Cancer, Non Small Cell Lung Cancer, Endometrium Cancer, Triple Negative Breast Cancer.

Is NCT07503808 still recruiting?

NCT07503808 is currently recruiting now. Last updated 31 March 2026.

Last reviewed 2026-03-31 · How we verify

NCT07503808

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

Recruiting now Phase 1 Last updated 31 March 2026

What this trial tests

Phase 1 trial testing IDE034 in Esophageal Squamous Cell Carcinoma in 150 participants. Currently enrolling.

Timeline

24 February 2026

Primary endpoint
30 July 2027

30 July 2027

Quick facts

Lead sponsor	IDEAYA Biosciences
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	150
Start date	24 February 2026
Primary completion	30 July 2027
Estimated completion	30 July 2027
Sites	5 locations across United States

Drugs / interventions tested

IDE034

Conditions studied

Esophageal Squamous Cell Carcinoma — all drugs for Esophageal Squamous Cell Carcinoma →
High Grade Serous Ovarian Cancer — all drugs for High Grade Serous Ovarian Cancer →
Head and Neck Squamous Cell Carcinoma — all drugs for Head and Neck Squamous Cell Carcinoma →
Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

IDEAYA Biosciences — full company profile →

Who can join

18 and older, any sex, with Esophageal Squamous Cell Carcinoma or High Grade Serous Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Esophageal Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT07385001 — A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as N · Phase 1, PHASE2 · recruiting
NCT07217171 — A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial · Phase 1 · recruiting
NCT07109726 — A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations · Phase 1, PHASE2 · recruiting
NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors · Phase 1 · recruiting
NCT06780111 — Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) · Phase 1, PHASE2 · recruiting

Other IDEAYA Biosciences trials

Trials by the same sponsor.

NCT07277413 — A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · Phase 1 · recruiting
NCT05987332 — IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma · Phase 2, PHASE3 · active not recruiting
NCT05907954 — (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma · Phase 2 · active not recruiting
NCT04794699 — Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion · Phase 1 · active not recruiting
NCT03947385 — Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07503808 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by IDEAYA Biosciences
Last refreshed: 31 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07503808.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing